Biogen stock tumbled 29% in a single day in March 2019 when the company said it was ending a Phase 3 trial of aducanumab, and investors thought the drug was dead.In a note out July 6, Bernstein Research analyst Ronny Gal said that the FDA’s recent decision not to approve Intercept Pharmaceuticals ’ (ICPT) application for its drug OCA to treat the liver disease NASH could be a bad sign for Biogen.